Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

NCT ID: NCT01987765

Last Updated: 2014-04-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 847 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-01-31
• Study Completion Date: 2012-09-30

Brief Summary

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.

Conditions

Conjunctivitis, Allergic

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Relestat Ophthalmic Solution 0.05%

Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.

Relestat Ophthalmic Solution 0.05%

Intervention Type: DRUG

Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.

Interventions

Relestat Ophthalmic Solution 0.05%

Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in clinical practice.

Exclusion Criteria

• None.

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Allergan

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Director

Role: STUDY_DIRECTOR

Allergan

Locations

Gangwon-do, , South Korea

Countries

South Korea

Other Identifiers

198027-A

Identifier Type: -

Identifier Source: org_study_id